{"entity":"bristol-myers-squibb","id":"ent_bristol-myers-squibb","name":"Bristol-Myers Squibb","wikidata":"Q266423","page":"https://asof.is/record/bristol-myers-squibb","summary":"As of November 12, 2025, Bristol-Myers Squibb was an American pharmaceutical company, headquartered in Princeton. Its CEO was Christopher S. Boerner, Ph.D, since 2023. It reported revenue of $48.30B for the period ended December 31, 2024.","title":null,"key_facts":[{"label":"CEO","value":"Christopher S. Boerner, Ph.D","note":"since 2023","claim":"clm_FF61856A3386"},{"label":"CFO","value":"David V. Elkins","claim":"clm_7B0B3B31B401"},{"label":"Headquarters","value":"Princeton","claim":"clm_C642296F0710"},{"label":"Revenue","value":"$48.30B","recorded":"48,300,000,000 United States dollar","note":"to 2024-12-31","claim":"clm_78596CC18E60"},{"label":"Ticker","value":"BMY · NYSE","claim":"clm_ED7EF0279BF9"}],"faq":[{"question":"Who is the CEO of Bristol-Myers Squibb?","answer":"Christopher S. Boerner, Ph.D, since 2023, as the AsOf record states with its sources."},{"question":"Where is Bristol-Myers Squibb headquartered?","answer":"Princeton."},{"question":"What is Bristol-Myers Squibb's revenue?","answer":"$48.30B for the period ended December 31, 2024."}],"as_of":"2025-11-12","known_by":null,"since":null,"fact_pages":[{"predicate":"ceo","page":"https://asof.is/record/bristol-myers-squibb/ceo","md":"https://asof.is/record/bristol-myers-squibb/ceo.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/ceo"},{"predicate":"chair","page":"https://asof.is/record/bristol-myers-squibb/chair","md":"https://asof.is/record/bristol-myers-squibb/chair.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/chair"},{"predicate":"cfo","page":"https://asof.is/record/bristol-myers-squibb/cfo","md":"https://asof.is/record/bristol-myers-squibb/cfo.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/cfo"},{"predicate":"coo","page":"https://asof.is/record/bristol-myers-squibb/coo","md":"https://asof.is/record/bristol-myers-squibb/coo.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/coo"},{"predicate":"board_member","page":"https://asof.is/record/bristol-myers-squibb/board_member","md":"https://asof.is/record/bristol-myers-squibb/board_member.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/board_member"},{"predicate":"headquarters","page":"https://asof.is/record/bristol-myers-squibb/headquarters","md":"https://asof.is/record/bristol-myers-squibb/headquarters.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/bristol-myers-squibb/revenue","md":"https://asof.is/record/bristol-myers-squibb/revenue.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/revenue"},{"predicate":"net_income","page":"https://asof.is/record/bristol-myers-squibb/net_income","md":"https://asof.is/record/bristol-myers-squibb/net_income.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/net_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/bristol-myers-squibb/quarterly_revenue","md":"https://asof.is/record/bristol-myers-squibb/quarterly_revenue.md","json":"https://asof.is/v1/entities/bristol-myers-squibb/quarterly_revenue"}],"products":[],"coverage":{"entity":"bristol-myers-squibb","name":"Bristol-Myers Squibb","kind":"organization","sources":[{"source":"wikidata","item":"Q266423","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":14272,"ticker":"BMY","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":534,"open":31,"retracted":0,"first":"1989-01-01","predicates":{"total_assets":{"claims":71,"open":1,"kind":"fact"},"total_equity":{"claims":71,"open":1,"kind":"fact"},"shares_outstanding":{"claims":69,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":56,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":56,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":76,"open":1,"kind":"fact"},"net_income":{"claims":19,"open":1,"kind":"fact"},"revenue":{"claims":19,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":56,"open":1,"kind":"fact"},"research_and_development":{"claims":19,"open":1,"kind":"fact"},"ticker":{"claims":2,"open":2,"kind":"identifier"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"country":{"claims":1,"open":1,"kind":"fact"},"chair":{"claims":1,"open":1,"kind":"fact"},"website":{"claims":1,"open":1,"kind":"identifier"},"cik":{"claims":1,"open":1,"kind":"identifier"},"x_username":{"claims":1,"open":1,"kind":"identifier"},"cfo":{"claims":1,"open":1,"kind":"fact"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":2,"open":1,"kind":"fact"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"board_member":{"claims":4,"open":4,"kind":"list"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"coo":{"claims":1,"open":1,"kind":"fact"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"ceo":{"claims":1,"open":1,"kind":"fact"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":527,"last_added":"2026-11-12","last_checked":"2026-11-12","last_verified":null},{"origin":"wikidata","label":"Wikidata statements that cite a reference URL (wikidata_ingest.py)","claims":7,"last_added":"2026-11-08","last_checked":"2026-11-11","last_verified":null}],"gaps":["posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_58CCCB4C5D70","predicate":"board_member","value":"Michael R. McMullen","valid_from":"2024-07-01","valid_to":null,"published":"2024-06-18","recorded":"2026-11-12","citation":{"plain":"AsOf. \"Bristol-Myers Squibb board member: Michael R. McMullen\", as of 2024-07-01. Claim clm_58CCCB4C5D70, https://asof.is/claim/clm_58CCCB4C5D70, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000114036124030533/0001140361-24-030533-index.htm.","url":"https://asof.is/claim/clm_58CCCB4C5D70","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000114036124030533/0001140361-24-030533-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2024-06-18T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-12","quote":"On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024.","url":"https://www.sec.gov/Archives/edgar/data/14272/000114036124030533/0001140361-24-030533-index.htm"}},{"id":"clm_B50E3002E109","predicate":"board_member","value":"Deepak L. Bhatt","valid_from":"2022-06-14","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb board member: Deepak L. Bhatt\", as of 2022-06-14. Claim clm_B50E3002E109, https://asof.is/claim/clm_B50E3002E109, accessed 2026-11-12. Source: https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Elects-Deepak-L.-Bhatt-M.D.-M.P.H.-to-Board-of-Directors/default.aspx.","url":"https://asof.is/claim/clm_B50E3002E109","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q266423","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Elects-Deepak-L.-Bhatt-M.D.-M.P.H.-to-Board-of-Directors/default.aspx","tier":"primary","publisher":null,"published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022.","url":"https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Elects-Deepak-L.-Bhatt-M.D.-M.P.H.-to-Board-of-Directors/default.aspx"}},{"id":"clm_F84214FDEDF2","predicate":"board_member","value":"Manuel Hidalgo Medina","valid_from":"2021-06-01","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb board member: Manuel Hidalgo Medina\", as of 2021-06-01. Claim clm_F84214FDEDF2, https://asof.is/claim/clm_F84214FDEDF2, accessed 2026-11-12. Source: https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Elects-Manuel-Hidalgo-Medina-M.D.-Ph.D.-to-Board-of-Directors/default.aspx.","url":"https://asof.is/claim/clm_F84214FDEDF2","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Elects-Manuel-Hidalgo-Medina-M.D.-Ph.D.-to-Board-of-Directors/default.aspx","tier":"primary","publisher":null,"published_at":null},{"url":"https://www.wikidata.org/wiki/Q266423","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Manuel Hidalgo Medina, M.D., Ph.D., to the Board, effective June 1, 2021.","url":"https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Elects-Manuel-Hidalgo-Medina-M.D.-Ph.D.-to-Board-of-Directors/default.aspx"}},{"id":"clm_EABE01FA350D","predicate":"board_member","value":"Derica W. Rice","valid_from":"2020-09-01","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb board member: Derica W. Rice\", as of 2020-09-01. Claim clm_EABE01FA350D, https://asof.is/claim/clm_EABE01FA350D, accessed 2026-11-12. Source: https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Board-Elects-Two-New-Independent-Directors/default.aspx.","url":"https://asof.is/claim/clm_EABE01FA350D","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q266423","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Board-Elects-Two-New-Independent-Directors/default.aspx","tier":"primary","publisher":null,"published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected two new independent directors, Ms. Paula A. Price and Mr. Derica W. Rice, who will join the Board, effective September 1, 2020.","url":"https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Board-Elects-Two-New-Independent-Directors/default.aspx"}},{"id":"clm_DE68C9E1A6BA","predicate":"board_member","value":"Karen Vousden","valid_from":"2018-01-01","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb board member: Karen Vousden\", as of 2018-01-01. Claim clm_DE68C9E1A6BA, https://asof.is/claim/clm_DE68C9E1A6BA, accessed 2026-11-12. Source: https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Names-Karen-Vousden-PhD-to-Board-of-Directors/default.aspx.","url":"https://asof.is/claim/clm_DE68C9E1A6BA","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q266423","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Names-Karen-Vousden-PhD-to-Board-of-Directors/default.aspx","tier":"primary","publisher":null,"published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Bristol-Myers Squibb Company (NYSE:BMY) today announced that its Board of Directors has elected Karen Vousden, Ph.D., to the Board, effective January 1, 2018.","url":"https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-Names-Karen-Vousden-PhD-to-Board-of-Directors/default.aspx"}},{"id":"clm_8F913554EE54","predicate":"cash_and_equivalents","value":"15,726,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb cash and equivalents: 15,726,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_8F913554EE54, https://asof.is/claim/clm_8F913554EE54, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_8F913554EE54","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_71B9DA11CD2A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_FF61856A3386","predicate":"ceo","value":"Christopher S. Boerner, Ph.D","valid_from":"2023-11-01","valid_to":null,"published":"2026-03-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb ceo: Christopher S. Boerner, Ph.D\", as of 2023-11-01. Claim clm_FF61856A3386, https://asof.is/claim/clm_FF61856A3386, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm.","url":"https://asof.is/claim/clm_FF61856A3386","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-03-25T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-08","quote":"Christopher S. Boerner, Ph.D. Board Chair & Chief Executive Officer of the Company Director Since: 2023 Age: 55 Board Committees • None Other Public Company Boards • Colgate-Palmolive Company Experience • Bristol Myers Squibb, Chief Executive Officer (November 2023-present)","url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm"}},{"id":"clm_3CCAF5DFD241","predicate":"ceo","value":"Christopher Boerner","valid_from":"2023-11-01","valid_to":null,"published":"2023-04-26","recorded":"2026-11-12","citation":{"plain":"AsOf. \"Bristol-Myers Squibb ceo: Christopher Boerner\", as of 2023-11-01. Claim clm_3CCAF5DFD241, https://asof.is/claim/clm_3CCAF5DFD241, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000114036123020605/0001140361-23-020605-index.htm.","url":"https://asof.is/claim/clm_3CCAF5DFD241","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000114036123020605/0001140361-23-020605-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2023-04-26T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/14272/000114036123022991/0001140361-23-022991-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2023-05-04T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/14272/000114036123050518/0001140361-23-050518-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2023-10-31T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-12","quote":"appointed Christopher Boerner, Ph.D., to serve as the Company’s Chief Operating Officer, effective April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023.","url":"https://www.sec.gov/Archives/edgar/data/14272/000114036123022991/0001140361-23-022991-index.htm"}},{"id":"clm_7B0B3B31B401","predicate":"cfo","value":"David V. Elkins","valid_from":null,"undated":true,"valid_to":null,"published":"2026-03-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb cfo: David V. Elkins\", undated. Claim clm_7B0B3B31B401, https://asof.is/claim/clm_7B0B3B31B401, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm.","url":"https://asof.is/claim/clm_7B0B3B31B401","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-03-25T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"David V. Elkins EVP and Chief Financial Officer Cristian Massacesi, M.D. EVP and Chief Medical Officer, Head of Development","url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm"}},{"id":"clm_62358F2F8937","predicate":"chair","value":"Christopher S. Boerner, Ph.D","valid_from":"2024-04-01","valid_to":null,"published":"2026-03-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb chair: Christopher S. Boerner, Ph.D\", as of 2024-04-01. Claim clm_62358F2F8937, https://asof.is/claim/clm_62358F2F8937, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm.","url":"https://asof.is/claim/clm_62358F2F8937","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-03-25T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-08","quote":"Christopher S. Boerner, Ph.D. Board Chair & Chief Executive Officer of the Company Director Since: 2023 Age: 55 Board Committees • None Other Public Company Boards • Colgate-Palmolive Company Experience • Bristol Myers Squibb, Chief Executive Officer (November 2023-present) • Board Chair (April 2024","url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm"}},{"id":"clm_772C4FAC73F0","predicate":"cik","value":"0000014272","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb cik: 0000014272\", undated. Claim clm_772C4FAC73F0, https://asof.is/claim/clm_772C4FAC73F0, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_772C4FAC73F0","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_DEC4AE840BD3","predicate":"coo","value":"Christopher Boerner","valid_from":"2023-04-26","valid_to":null,"published":"2023-04-26","recorded":"2026-11-12","citation":{"plain":"AsOf. \"Bristol-Myers Squibb coo: Christopher Boerner\", as of 2023-04-26. Claim clm_DEC4AE840BD3, https://asof.is/claim/clm_DEC4AE840BD3, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000114036123020605/0001140361-23-020605-index.htm.","url":"https://asof.is/claim/clm_DEC4AE840BD3","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000114036123020605/0001140361-23-020605-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2023-04-26T00:00:00+00:00"},{"url":"https://www.sec.gov/Archives/edgar/data/14272/000114036123022991/0001140361-23-022991-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2023-05-04T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-12","quote":"appointed Christopher Boerner, Ph.D., to serve as the Company’s Chief Operating Officer, effective April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023.","url":"https://www.sec.gov/Archives/edgar/data/14272/000114036123022991/0001140361-23-022991-index.htm"}},{"id":"clm_52D62022AD52","predicate":"country","value":"United States","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb country: United States\", undated. Claim clm_52D62022AD52, https://asof.is/claim/clm_52D62022AD52, accessed 2026-11-12. Source: https://www.lobbyfacts.eu/datacard/bristol-myers-squibb-company?rid=04437556781-76.","url":"https://asof.is/claim/clm_52D62022AD52","accessed":"2026-11-12"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.lobbyfacts.eu/datacard/bristol-myers-squibb-company?rid=04437556781-76","tier":"secondary","publisher":null,"published_at":null},{"url":"https://www.wikidata.org/wiki/Q266423","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-10","quote":"Address Head Office Route 206Province Line Road Princeton, New Jersey 08543 UNITED STATES","url":"https://www.lobbyfacts.eu/datacard/bristol-myers-squibb-company?rid=04437556781-76"}},{"id":"clm_B055BC429569","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb fiscal year end: 12-31\", undated. Claim clm_B055BC429569, https://asof.is/claim/clm_B055BC429569, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_B055BC429569","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_C642296F0710","predicate":"headquarters","value":"Princeton","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb headquarters: Princeton\", undated. Claim clm_C642296F0710, https://asof.is/claim/clm_C642296F0710, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_C642296F0710","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_7C0328B0E90C","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb listed on: NYSE\", undated. Claim clm_7C0328B0E90C, https://asof.is/claim/clm_7C0328B0E90C, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_7C0328B0E90C","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_93176D9F8458","predicate":"net_income","value":"-8,948,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb net income: -8,948,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_93176D9F8458, https://asof.is/claim/clm_93176D9F8458, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm.","url":"https://asof.is/claim/clm_93176D9F8458","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_52D44073C808","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-12"}},{"id":"clm_B6387AF1FB92","predicate":"quarterly_net_income","value":"2,201,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb quarterly net income: 2,201,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_B6387AF1FB92, https://asof.is/claim/clm_B6387AF1FB92, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_B6387AF1FB92","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_59B16D5CFE58","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_B92B3F0BD51E","predicate":"quarterly_operating_income","value":"1,402,000,000 United States dollar","valid_from":"2012-03-31","valid_to":null,"published":"2012-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb quarterly operating income: 1,402,000,000 United States dollar\", as of 2012-03-31. Claim clm_B92B3F0BD51E, https://asof.is/claim/clm_B92B3F0BD51E, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000119312512184689/0001193125-12-184689-index.htm.","url":"https://asof.is/claim/clm_B92B3F0BD51E","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000119312512184689/0001193125-12-184689-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-04-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2012, filed 2012-04-26"}},{"id":"clm_F60212FAE72C","predicate":"quarterly_research_and_development","value":"2,528,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb quarterly research and development: 2,528,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_F60212FAE72C, https://asof.is/claim/clm_F60212FAE72C, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_F60212FAE72C","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_66E70FD09231","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_BB784B853512","predicate":"quarterly_revenue","value":"12,222,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb quarterly revenue: 12,222,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_BB784B853512, https://asof.is/claim/clm_BB784B853512, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_BB784B853512","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3BBDC1786FBC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_B021E66EA136","predicate":"registrant_name","value":"BRISTOL MYERS SQUIBB CO","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb registrant name: BRISTOL MYERS SQUIBB CO\", undated. Claim clm_B021E66EA136, https://asof.is/claim/clm_B021E66EA136, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_B021E66EA136","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_CC290D20ACB7","predicate":"research_and_development","value":"11,159,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb research and development: 11,159,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_CC290D20ACB7, https://asof.is/claim/clm_CC290D20ACB7, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm.","url":"https://asof.is/claim/clm_CC290D20ACB7","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1D1D9926921B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2024, filed 2025-02-12"}},{"id":"clm_78596CC18E60","predicate":"revenue","value":"48,300,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb revenue: 48,300,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_78596CC18E60, https://asof.is/claim/clm_78596CC18E60, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm.","url":"https://asof.is/claim/clm_78596CC18E60","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BB9F55DFC7A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/0000014272-25-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2024, filed 2025-02-12"}},{"id":"clm_5DF65CC84443","predicate":"shares_outstanding","value":"2,035,753,027 shares","valid_from":"2025-10-23","valid_to":"2026-02-04","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb shares outstanding: 2,035,753,027 shares\", as of 2025-10-23 (until 2026-02-04). Claim clm_5DF65CC84443, https://asof.is/claim/clm_5DF65CC84443, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_5DF65CC84443","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7BDDFBA6A82F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_DF7B0F2F37F6","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_DF7B0F2F37F6, https://asof.is/claim/clm_DF7B0F2F37F6, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_DF7B0F2F37F6","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_48211D1EBA75","predicate":"state_of_incorporation","value":"DE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb state of incorporation: DE\", undated. Claim clm_48211D1EBA75, https://asof.is/claim/clm_48211D1EBA75, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_48211D1EBA75","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_ED7EF0279BF9","predicate":"ticker","value":"BMY","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb ticker: BMY\", undated. Claim clm_ED7EF0279BF9, https://asof.is/claim/clm_ED7EF0279BF9, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_ED7EF0279BF9","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_1EFB3D1960DA","predicate":"ticker","value":"CELG-RI","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb ticker: CELG-RI\", undated. Claim clm_1EFB3D1960DA, https://asof.is/claim/clm_1EFB3D1960DA, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272.","url":"https://asof.is/claim/clm_1EFB3D1960DA","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B080F3CCA436","predicate":"total_assets","value":"96,889,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb total assets: 96,889,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_B080F3CCA436, https://asof.is/claim/clm_B080F3CCA436, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_B080F3CCA436","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_16735433DCF9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_3AA608585C53","predicate":"total_equity","value":"18,552,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb total equity: 18,552,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_3AA608585C53, https://asof.is/claim/clm_3AA608585C53, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm.","url":"https://asof.is/claim/clm_3AA608585C53","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D808E9CABB64","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000149/0000014272-25-000149-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_6C58446D45ED","predicate":"website","value":"https://www.bms.com/","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb website: https://www.bms.com/\", undated. Claim clm_6C58446D45ED, https://asof.is/claim/clm_6C58446D45ED, accessed 2026-11-12. Source: https://www.wikidata.org/wiki/Q266423.","url":"https://asof.is/claim/clm_6C58446D45ED","accessed":"2026-11-12"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q266423","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-11","quote":"Bristol Myers Squibb - Global Biopharmaceutical Company.","url":"https://www.bms.com/"}},{"id":"clm_7954DAE3098C","predicate":"x_username","value":"bmsnews","valid_from":"2009-04-21","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Bristol-Myers Squibb x username: bmsnews\", as of 2009-04-21. Claim clm_7954DAE3098C, https://asof.is/claim/clm_7954DAE3098C, accessed 2026-11-12. Source: https://www.wikidata.org/wiki/Q266423.","url":"https://asof.is/claim/clm_7954DAE3098C","accessed":"2026-11-12"},"confidence":0.6,"status":"unverified","assertable":false,"why_not":"unverified","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q266423","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"https://twitter.com/BMSNEWS","url":"https://www.bms.com/"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at.","unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it."},"checked_by":{"page-read":"its source page states the value and the date","sec-filing":"parsed from the SEC filing","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}